140 related articles for article (PubMed ID: 38331629)
1. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [
Eisazadeh R; Shahbazi-Akbari M; Mirshahvalad SA; Pirich C; Beheshti M
Semin Nucl Med; 2024 Mar; 54(2):293-301. PubMed ID: 38331629
[TBL] [Abstract][Full Text] [Related]
2. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [
Mirshahvalad SA; Eisazadeh R; Shahbazi-Akbari M; Pirich C; Beheshti M
Semin Nucl Med; 2024 Jan; 54(1):171-180. PubMed ID: 37752032
[TBL] [Abstract][Full Text] [Related]
3. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
4. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
6. (18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study.
Bolcaen J; Descamps B; Deblaere K; Boterberg T; De Vos Pharm F; Kalala JP; Van den Broecke C; Decrock E; Leybaert L; Vanhove C; Goethals I
Nucl Med Biol; 2015 Jan; 42(1):38-45. PubMed ID: 25218024
[TBL] [Abstract][Full Text] [Related]
7. The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI.
Santo G; Laudicella R; Linguanti F; Nappi AG; Abenavoli E; Vergura V; Rubini G; Sciagrà R; Arnone G; Schillaci O; Minutoli F; Baldari S; Quartuccio N; Bisdas S
Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453892
[TBL] [Abstract][Full Text] [Related]
8. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
Gulyás B; Halldin C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
[TBL] [Abstract][Full Text] [Related]
9. Performance of 18F-FDG, 11C-Methionine, and 18F-FET PET for Glioma Grading: A Meta-analysis.
Katsanos AH; Alexiou GA; Fotopoulos AD; Jabbour P; Kyritsis AP; Sioka C
Clin Nucl Med; 2019 Nov; 44(11):864-869. PubMed ID: 31205150
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Accuracy of PET Tracers for the Differentiation of Tumor Progression from Treatment-Related Changes in High-Grade Glioma: A Systematic Review and Metaanalysis.
de Zwart PL; van Dijken BRJ; Holtman GA; Stormezand GN; Dierckx RAJO; Jan van Laar P; van der Hoorn A
J Nucl Med; 2020 Apr; 61(4):498-504. PubMed ID: 31541032
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
[TBL] [Abstract][Full Text] [Related]
12. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas.
Plotkin M; Blechschmidt C; Auf G; Nyuyki F; Geworski L; Denecke T; Brenner W; Stockhammer F
Eur Radiol; 2010 Oct; 20(10):2496-502. PubMed ID: 20521054
[TBL] [Abstract][Full Text] [Related]
13. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[
Langen KJ; Stoffels G; Filss C; Heinzel A; Stegmayr C; Lohmann P; Willuweit A; Neumaier B; Mottaghy FM; Galldiks N
Methods; 2017 Nov; 130():124-134. PubMed ID: 28552264
[TBL] [Abstract][Full Text] [Related]
14. Treatment-Related Uptake of
Geisler S; Stegmayr C; Niemitz N; Lohmann P; Rapp M; Stoffels G; Willuweit A; Galldiks N; Filss C; Sabel MC; Coenen HH; Shah NJ; Langen KJ
J Nucl Med; 2019 Oct; 60(10):1373-1379. PubMed ID: 30850492
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.
Floeth FW; Pauleit D; Sabel M; Stoffels G; Reifenberger G; Riemenschneider MJ; Jansen P; Coenen HH; Steiger HJ; Langen KJ
J Nucl Med; 2007 Apr; 48(4):519-27. PubMed ID: 17401087
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
Bashir A; Brennum J; Broholm H; Law I
J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
[TBL] [Abstract][Full Text] [Related]
19. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M
Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820
[TBL] [Abstract][Full Text] [Related]
20. 18F-FET PET differentiation of ring-enhancing brain lesions.
Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
